Scarica l'app Stockscreener
2.26
5.61%
0.12
Dopo l'orario di chiusura:
2.33
0.07
+3.10%
Grace Therapeutics Inc Borsa (GRCE) Ultime notizie
Grace Therapeutics (GRCE) 10% holder buys more stock - Stock Titan
CEO Prashant Kohli Buys 100,000 Shares of Grace Therapeutics Inc (GRCE) - GuruFocus
Grace Therapeutics CEO Kohli acquires $214,000 in common stock - Investing.com
Grace Therapeutics CEO Kohli acquires $214,000 in common stock By Investing.com - Investing.com India
CEO of Grace Therapeutics (GRCE) adds 100K shares - Stock Titan
Grace Therapeutics (GRCE) Dips 1.0% to $2.08, Holds Above Key SupportPullback Trade - dars.gov.et
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
GRCE Stock Plunges 45% After FDA Rejects Brain Injury Drug — Company Says Concerns Are Fixable - Stocktwits
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference - The Manila Times
A drug company CEO's presentation goes online Sept. 11. He'll meet investors in New York. - Stock Titan
Grace Therapeutics (GRCE) awards finance chief options vesting over three years - Stock Titan
Grace Therapeutics (GRCE) grants CEO options at $2.12 - Stock Titan
Grace Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Grace Therapeutics clears FDA safety hurdles for GTx-104 - scanx.trade
Opaleye Management Inc. Expands Stake in Grace Therapeutics Inc (GRCE) Despite Market Headwinds - GuruFocus
Grace TherapeuticsSelling Stockholders May Resell Up To 4,761,904 Shares Of Common StockSEC Filing - TradingView
Grace (GRCE) Quarterly Results: EPS Lands Above Forecast at the Close; Post-Earnings: The Stock Ends Up 2.80% in the Latest SessionCore Business Growth - vinanet.vn
Grace Therapeutics files prospectus for 4.762m share sale - scanx.trade
Grace (GRCE) Earnings Reading: EPS Exceeds Its Estimate in Latest Trading; Price Move: Shares Move 2.80% Higher - vinanet.vn
Grace (GRCE) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison at the Close; Trading Response: Shares Finish 1.88% Higher in the Latest ReadingTech Earnings Analysis - vinanet.vn
Opaleye Management buys $24,206 of Grace Therapeutics stock By Investing.com - Investing.com Canada
Opaleye Management buys $24,206 of Grace Therapeutics stock - Investing.com
Grace Therapeutics (GRCE) holder lifts indirect stake to 2.76M shares - Stock Titan
Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating, Announces Target Price $4 - Moomoo
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
Grace Therapeutics (GRCE): ADAR1 group discloses 9.9% beneficial stake via warrants - Stock Titan
Grace Therapeutics (GRCE) investor group reports 6.75% stake via convertibles - Stock Titan
Grace Therapeutics, Inc. Reports Impairment charges for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics, Inc. (NASDAQ: GRCE) Share Price, GRCE Stock News, GRCE Share Price & Updates - Kalkine
GRCE Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 74.42% EPS SurpriseManagement Guidance Update - vinanet.vn
Grace Therapeutics Q1 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Form 8K Grace Therapeutics, Inc For: 13 August By Investing.com - Investing.com Nigeria
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Reports $15.8 Million First-Quarter Net Loss - Quiver Quantitative
Grace Therapeutics, Inc. Q1 2027: Net loss $(15.8)M, EPS $(0.91) — 10-Q Summary - TradingView
Grace Therapeutics (GRCE) books $13.5M R&D impairment, extends cash runway to 2028 - Stock Titan
Grace Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics (GRCE) completes $9.99M Rule 506(b) private equity raise - Stock Titan
GRCE Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers a 74.42% Surprise Despite No RevenuePost-Earnings Drift - vinanet.vn
Grace Therapeutics (GRCE): Opaleye reports 2.75M-share, 13.07% ownership stake - Stock Titan
Grace Therapeutics, Inc. Revenue Breakdown – NASDAQ:GRCE - TradingView
GRCE Q2 2026 Earnings: Loss Narrows Sharply as EPS Beats Estimates by 74.4%Earnings Weakness Phase - vinanet.vn
Grace Therapeutics Raises Capital to Advance GTx-104 Program - TipRanks
Grace Therapeutics Raises $10 Million in Private Placement, Grants Registration Rights - TradingView
Grace Therapeutics announces securities purchase agreement for $10M private placement - ROI-NJ
Grace Therapeutics (GRCE) Raises $10M in Private Placement Amid High Price-to-Sales Valuation - GuruFocus
GRCE Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
Grace Therapeutics Secures $10M Private Placement Agreement - Intellectia AI
Grace Therapeutics Announces $10 Million Private Placement Financing to Support GTx-104 Development - quiverquant.com
Grace Therapeutics Expects Funding to Extend Cash Runway Through 2028 - Stock Titan
Grace Therapeutics raises $10 million in private placement By Investing.com - Investing.com Australia
Grace Therapeutics raises $10 million in private placement - Investing.com
Grace Therapeutics raises $10M in private place... - Pluang
Grace Therapeutics Announces $10 Million Private Placement - Moomoo
Grace Therapeutics prices USD 10 million private placement at USD 2.1 per share - Bitget
Grace Therapeutics, Inc. announced that it expects to receive $9.999998 million in funding - marketscreener.com
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):